IN BRIEF: ValiRx establishes veterinary oncology-focused subsidiary
ValiRx PLC - London-based life science company - Establishes wholly owned subsidiary ValiRx Animal Health Ltd to develop and commercialise its oncology assets in the veterinary market. The subsidiary will use preclinical work from ValiRx human programmes to pursue comparative oncology opportunities. "There is a strong scientific rationale, as well as market opportunities, for this ethical approach and several examples of companies that have followed this route," says Chief Executive Officer Mark Eccleston, who adds that the three key areas of focus will be Osteosarcoma, Lymphoma and Hemangiosarcoma. ValiRx said specialist veterinary venture capitalist funds have been identified and approached with the intention that the subsidiary will be independently funded. The global veterinary oncology market was valued at USD1.58 billion in 2024 and is projected to reach USD4.86 billion by 2034, representing a compound annual growth rate of 12%. Read More